| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Laboratory of Molecular and Cellular Therapy, Department of Physiology-Immunology, Medical School of the Vrije Universiteit Brussel, 1090 Brussels [A. B., C. H., S. T., A. M., K. T.], and Ludwig Institute for Cancer Research-Brussels Branch, 1200 Brussels [Y. Z., P. v. d. B.], Belgium
For the induction of an optimal immune response against cancer or infections not only CD8+ CTLs but also CD4+ T helper cells must be induced, in particular IFN-
-secreting type 1 T helper cells. Several strategies have been explored to target tumor-associated antigens to the HLA class II processing compartments. We engineered a genetic construct encoding an invariant chain (Ii) protein where the CLIP region has been replaced by sequences encoding HLA class II-restricted MAGE-A3 epitopes. Monocyte-derived dendritic cells (DCs) were electroporated with in vitro transcribed mRNA encoding a modified Ii protein containing the HLA-DP4-restricted MAGE-A3 epitope. The capacity of these electroporated DCs to stimulate a MAGE-A3-specific T-cell clone was compared at different stages of DC maturation with the T-cell stimulatory capacity of DCs pulsed with the synthetic peptide. After electroporation, the T-cell stimulatory capacity was shown to be high and long lasting, whereas the stimulatory capacity of peptide-pulsed DCs decreased rapidly. Upon coculture with epitope-specific T cells, electroporated immature DCs expressed enhanced levels of costimulatory molecules, HLA class II molecules, and CD83, suggesting the induction of maturation. The electroporated DCs can be frozen and thawed without losing their capability to stimulate the specific T-cell clone in vitro, and they are able to stimulate unprimed CD4+ T cells specific to the HLA-DP4-restricted MAGE-A3 epitope in vitro. Similar results were obtained with a recombinant Ii containing the MAGE-A3 epitope presented in the context of HLA-DR13.
This article has been cited by other articles:
![]() |
S. Kreiter, A. Selmi, M. Diken, M. Sebastian, P. Osterloh, H. Schild, C. Huber, O. Tureci, and U. Sahin Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals J. Immunol., January 1, 2008; 180(1): 309 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Motomura, S. Senju, T. Nakatsura, H. Matsuyoshi, S. Hirata, M. Monji, H. Komori, D. Fukuma, H. Baba, and Y. Nishimura Embryonic Stem Cell-Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10 Cancer Res., February 15, 2006; 66(4): 2414 - 2422. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bonehill, C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. van der Bruggen, and K. Thielemans Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules J. Immunol., June 1, 2004; 172(11): 6649 - 6657. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |